373 related articles for article (PubMed ID: 25568350)
1. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice.
Crudele JM; Finn JD; Siner JI; Martin NB; Niemeyer GP; Zhou S; Mingozzi F; Lothrop CD; Arruda VR
Blood; 2015 Mar; 125(10):1553-61. PubMed ID: 25568350
[TBL] [Abstract][Full Text] [Related]
2. Efficient induction of immune tolerance to coagulation factor IX following direct intramuscular gene transfer.
Cohn EF; Zhuo J; Kelly ME; Chao HJ
J Thromb Haemost; 2007 Jun; 5(6):1227-36. PubMed ID: 17362228
[TBL] [Abstract][Full Text] [Related]
3. Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B.
Arruda VR; Stedman HH; Haurigot V; Buchlis G; Baila S; Favaro P; Chen Y; Franck HG; Zhou S; Wright JF; Couto LB; Jiang H; Pierce GF; Bellinger DA; Mingozzi F; Nichols TC; High KA
Blood; 2010 Jun; 115(23):4678-88. PubMed ID: 20335222
[TBL] [Abstract][Full Text] [Related]
4. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy.
Mount JD; Herzog RW; Tillson DM; Goodman SA; Robinson N; McCleland ML; Bellinger D; Nichols TC; Arruda VR; Lothrop CD; High KA
Blood; 2002 Apr; 99(8):2670-6. PubMed ID: 11929752
[TBL] [Abstract][Full Text] [Related]
5. FIX-Triple, a gain-of-function factor IX variant, improves haemostasis in mouse models without increased risk of thrombosis.
Kao CY; Lin CN; Yu IS; Tao MH; Wu HL; Shi GY; Yang YL; Kao JT; Lin SW
Thromb Haemost; 2010 Aug; 104(2):355-65. PubMed ID: 20539913
[TBL] [Abstract][Full Text] [Related]
6. Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B.
Harding TC; Koprivnikar KE; Tu GH; Zayek N; Lew S; Subramanian A; Sivakumaran A; Frey D; Ho K; VanRoey MJ; Nichols TC; Bellinger DA; Yendluri S; Waugh J; McArthur J; Veres G; Donahue BA
Gene Ther; 2004 Jan; 11(2):204-13. PubMed ID: 14712305
[TBL] [Abstract][Full Text] [Related]
7. Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors.
Chao H; Monahan PE; Liu Y; Samulski RJ; Walsh CE
Mol Ther; 2001 Sep; 4(3):217-22. PubMed ID: 11545612
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1.
Arruda VR; Schuettrumpf J; Herzog RW; Nichols TC; Robinson N; Lotfi Y; Mingozzi F; Xiao W; Couto LB; High KA
Blood; 2004 Jan; 103(1):85-92. PubMed ID: 12969984
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application.
Monahan PE; Lothrop CD; Sun J; Hirsch ML; Kafri T; Kantor B; Sarkar R; Tillson DM; Elia JR; Samulski RJ
Mol Ther; 2010 Nov; 18(11):1907-16. PubMed ID: 20700109
[TBL] [Abstract][Full Text] [Related]
10. Persistent expression of canine factor IX in hemophilia B canines.
Chao H; Samulski R; Bellinger D; Monahan P; Nichols T; Walsh C
Gene Ther; 1999 Oct; 6(10):1695-704. PubMed ID: 10516718
[TBL] [Abstract][Full Text] [Related]
11. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose.
Wu Z; Sun J; Zhang T; Yin C; Yin F; Van Dyke T; Samulski RJ; Monahan PE
Mol Ther; 2008 Feb; 16(2):280-9. PubMed ID: 18059373
[TBL] [Abstract][Full Text] [Related]
12. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy.
Niemeyer GP; Herzog RW; Mount J; Arruda VR; Tillson DM; Hathcock J; van Ginkel FW; High KA; Lothrop CD
Blood; 2009 Jan; 113(4):797-806. PubMed ID: 18957684
[TBL] [Abstract][Full Text] [Related]
13. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy.
Jiang H; Couto LB; Patarroyo-White S; Liu T; Nagy D; Vargas JA; Zhou S; Scallan CD; Sommer J; Vijay S; Mingozzi F; High KA; Pierce GF
Blood; 2006 Nov; 108(10):3321-8. PubMed ID: 16868252
[TBL] [Abstract][Full Text] [Related]
14. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver.
Wang L; Nichols TC; Read MS; Bellinger DA; Verma IM
Mol Ther; 2000 Feb; 1(2):154-8. PubMed ID: 10933925
[TBL] [Abstract][Full Text] [Related]
15. Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer.
Cooper M; Nayak S; Hoffman BE; Terhorst C; Cao O; Herzog RW
Hum Gene Ther; 2009 Jul; 20(7):767-76. PubMed ID: 19309290
[TBL] [Abstract][Full Text] [Related]
16. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy.
Herzog RW; Fields PA; Arruda VR; Brubaker JO; Armstrong E; McClintock D; Bellinger DA; Couto LB; Nichols TC; High KA
Hum Gene Ther; 2002 Jul; 13(11):1281-91. PubMed ID: 12162811
[TBL] [Abstract][Full Text] [Related]
17. Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy.
Wang L; Calcedo R; Nichols TC; Bellinger DA; Dillow A; Verma IM; Wilson JM
Blood; 2005 Apr; 105(8):3079-86. PubMed ID: 15637142
[TBL] [Abstract][Full Text] [Related]
18. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.
Manno CS; Chew AJ; Hutchison S; Larson PJ; Herzog RW; Arruda VR; Tai SJ; Ragni MV; Thompson A; Ozelo M; Couto LB; Leonard DG; Johnson FA; McClelland A; Scallan C; Skarsgard E; Flake AW; Kay MA; High KA; Glader B
Blood; 2003 Apr; 101(8):2963-72. PubMed ID: 12515715
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.
Nathwani AC; Rosales C; McIntosh J; Rastegarlari G; Nathwani D; Raj D; Nawathe S; Waddington SN; Bronson R; Jackson S; Donahue RE; High KA; Mingozzi F; Ng CY; Zhou J; Spence Y; McCarville MB; Valentine M; Allay J; Coleman J; Sleep S; Gray JT; Nienhuis AW; Davidoff AM
Mol Ther; 2011 May; 19(5):876-85. PubMed ID: 21245849
[TBL] [Abstract][Full Text] [Related]
20. Sustained phenotypic correction of canine hemophilia B after systemic administration of helper-dependent adenoviral vector.
Brunetti-Pierri N; Nichols TC; McCorquodale S; Merricks E; Palmer DJ; Beaudet AL; Ng P
Hum Gene Ther; 2005 Jul; 16(7):811-20. PubMed ID: 16000063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
